Outlining Advances Made in Ovarian Cancer in Oklahoma City
We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.
Related Articles
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care
Since it’s implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and…
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care
Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
Community Practice Training During Fellowship Often Falls Short
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.
Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The Diagnosis and Prevalence of Secondary AML
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Sasanlimab Plus BCG Could Alter Treatment Paradigm in BCG-Naive, High-Risk NMIBC
Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting